A Study of MKC-442 in Combination With Other Anti-HIV Drugs

NCT00002412 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2005-06-24

No results posted yet for this study

Summary

The purpose of this study is to see if it is safe and effective to give MKC-442 plus stavudine (d4T) plus didanosine (ddI) plus hydroxyurea.

Conditions

  • HIV Infections

Interventions

DRUG

Emivirine

DRUG

Hydroxyurea

DRUG

Stavudine

DRUG

Didanosine

Sponsors & Collaborators

  • Triangle Pharmaceuticals

    lead INDUSTRY

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002412 on ClinicalTrials.gov